213 related articles for article (PubMed ID: 33468559)
21. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
22. RECQL: a new breast cancer susceptibility gene.
Banerjee T; Brosh RM
Cell Cycle; 2015; 14(22):3540-3. PubMed ID: 26125302
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
Arora A; Parvathaneni S; Aleskandarany MA; Agarwal D; Ali R; Abdel-Fatah T; Green AR; Ball GR; Rakha EA; Ellis IO; Sharma S; Madhusudan S
Mol Cancer Ther; 2017 Jan; 16(1):239-250. PubMed ID: 27837030
[TBL] [Abstract][Full Text] [Related]
24. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.
Eeckhoute J; Carroll JS; Geistlinger TR; Torres-Arzayus MI; Brown M
Genes Dev; 2006 Sep; 20(18):2513-26. PubMed ID: 16980581
[TBL] [Abstract][Full Text] [Related]
25. AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.
Bhat-Nakshatri P; Wang G; Appaiah H; Luktuke N; Carroll JS; Geistlinger TR; Brown M; Badve S; Liu Y; Nakshatri H
Mol Cell Biol; 2008 Dec; 28(24):7487-503. PubMed ID: 18838536
[TBL] [Abstract][Full Text] [Related]
26. Gene expression signature of estrogen receptor alpha status in breast cancer.
Abba MC; Hu Y; Sun H; Drake JA; Gaddis S; Baggerly K; Sahin A; Aldaz CM
BMC Genomics; 2005 Mar; 6():37. PubMed ID: 15762987
[TBL] [Abstract][Full Text] [Related]
27. GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells.
Niang B; Jin L; Chen X; Guo X; Zhang H; Wu Q; Padhiar AA; Xiao M; Fang D; Zhang J
Mol Cell Biochem; 2016 Jan; 411(1-2):393-402. PubMed ID: 26541755
[TBL] [Abstract][Full Text] [Related]
28. Estrogen induces dynamic ERα and RING1B recruitment to control gene and enhancer activities in luminal breast cancer.
Zhang Y; Chan HL; Garcia-Martinez L; Karl DL; Weich N; Slingerland JM; Verdun RE; Morey L
Sci Adv; 2020 Jun; 6(23):eaaz7249. PubMed ID: 32548262
[TBL] [Abstract][Full Text] [Related]
29. Nuclear accumulation of MKL1 in luminal breast cancer cells impairs genomic activity of ERα and is associated with endocrine resistance.
Jehanno C; Fernandez-Calero T; Habauzit D; Avner S; Percevault F; Jullion E; Le Goff P; Coissieux MM; Muenst S; Marin M; Michel D; Métivier R; Flouriot G
Biochim Biophys Acta Gene Regul Mech; 2020 May; 1863(5):194507. PubMed ID: 32113984
[TBL] [Abstract][Full Text] [Related]
30. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
Lu W; Katzenellenbogen BS
Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
[TBL] [Abstract][Full Text] [Related]
31. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
32. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
33. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.
Bernardo GM; Lozada KL; Miedler JD; Harburg G; Hewitt SC; Mosley JD; Godwin AK; Korach KS; Visvader JE; Kaestner KH; Abdul-Karim FW; Montano MM; Keri RA
Development; 2010 Jun; 137(12):2045-54. PubMed ID: 20501593
[TBL] [Abstract][Full Text] [Related]
34. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
Wen W; Chen Z; Bao J; Long Q; Shu XO; Zheng W; Guo X
Nat Commun; 2021 Sep; 12(1):5318. PubMed ID: 34518541
[TBL] [Abstract][Full Text] [Related]
35. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer.
Ung M; Ma X; Johnson KC; Christensen BC; Cheng C
Epigenetics; 2014 Apr; 9(4):523-32. PubMed ID: 24434785
[TBL] [Abstract][Full Text] [Related]
36. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.
Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA
BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297
[TBL] [Abstract][Full Text] [Related]
37. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells.
Laganière J; Deblois G; Giguère V
Mol Endocrinol; 2005 Jun; 19(6):1584-92. PubMed ID: 15831516
[TBL] [Abstract][Full Text] [Related]
38. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.
Frietze S; O'Geen H; Littlepage LE; Simion C; Sweeney CA; Farnham PJ; Krig SR
BMC Genomics; 2014 Jun; 15(1):520. PubMed ID: 24962896
[TBL] [Abstract][Full Text] [Related]
39. Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells.
Zhang H; Xie X; Zhu X; Zhu J; Hao C; Lu Q; Ding L; Liu Y; Zhou L; Liu Y; Huang C; Wen C; Ye Q
J Biol Chem; 2005 Dec; 280(52):43188-97. PubMed ID: 16219765
[TBL] [Abstract][Full Text] [Related]
40. FOXP1 and estrogen signaling in breast cancer.
Ijichi N; Ikeda K; Horie-Inoue K; Inoue S
Vitam Horm; 2013; 93():203-12. PubMed ID: 23810008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
